Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.09, read 2026-10-30
Ethical passes the values gate
Price81.26 USD
Fair value125.00
Ethical score81.3/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-10-17Read Accumulation80.56+0.9% to today ✓Markdown gives way to Accumulation after a 7% rise in 6 days
2026-10-11Read Markdown75.10+8.2% to today Distribution gives way to Markdown
2026-10-02Read Distribution75.10+8.2% to today Markup gives way to Distribution after an 8% slide in 8 weeks
2026-08-07Read Markup81.71-0.6% to today Distribution gives way to Markup after an 8% rise in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Omnicom Group holds its Markup at $81.26. The statistical read favours the buyers, held for 6 days.
As held on the ledger · 2026-10-30
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 6 days
Price at the screen
$81.26
Valuation
82.08 trailing · 7.29 forward price to earnings
Values screen
PASS· score 81.3
Beta
0.70
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
19.73%
Below 33%
Interest-bearing debt is just 19.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.12%
Below 33%
Cash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit.
Pass
Receivables
39.10%
Below 49%
Money owed to the company is 39.1% of assets, under the 49% limit.
Pass
Revenue purity
0.56%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Omnicom clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 20%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-30. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when OMC's ethical verdict changes
Today OMC passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads OPPORTUNITY: it trades at roughly a 54% discount to our $125.00 fair value, weak competitive moat, 59.10% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. A 53.8% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +23% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Ad budgets still flow through every cycle
Think of advertising as the oxygen brands keep buying even when times tighten. Omnicom sits at the centre of that spend, yet the shares trade at just 6.7 times forward earnings with a 54 percent gap to our fair value of 125.62. Revenue jumped 69 percent while the ethical screen cleared without issue and twelve analysts still cluster around a 100 target.
The low multiple reflects a business that keeps delivering reach across media, precision marketing and healthcare communications. A margin of safety this wide on a name that passes our screens is rare in communication services right now.
Yet profit margins sit at zero and return on equity is only 2 percent, with a weak moat leaving it exposed to client cuts the moment budgets tighten. Advertising is a classic cyclical business, so the cheap earnings multiple may simply mark peak-cycle numbers rather than a bargain. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
OMC trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$77.77-3.5%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100.
2026-10-22Accumulation$80.56+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$80.56+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Accumulation$80.56+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Accumulation$80.56+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$80.56+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$80.72+5.5%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$76.48+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markdown$76.48+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $100. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.